MSH3 ESPRESSION STATUS TO DETERMINE CANCERYGEN CELL RESPONSIBILITY TO CHEMOTHERAPIC TREATMENT WITH PARP INHIBITORS AND PLATINUM DRUGS

摘要

MSH3 EXPRESSION STATUS FOR DETERMINING CANCERYGEN CELL RESPONSIBILITY TO CHEMOTHERAPIC TREATMENT WITH PARP INHIBITORS AND PLATINUM DRUGS. Disclosed herein are methods for treating a patient at risk or diagnosed with colorectal cancer. The method of the present invention determines overall expression of MSH3 in cells suspected to be a patient's colorectal cancer cells and provides for the efficacy of therapy with an antineoplastic genotoxic agent for patient treatment, wherein a decrease in overall expression of MSH3 in the cells. Patient cells, when compared with MSH3 expression in normal scolectal cells, indicate a predisposition to responsiveness to genotoxic antineoplastic agent therapy, wherein therapy comprises administering an effective amount of genotoxic antineoplastic agent therapy to patients.